切换导航
  • 比较产品
我的购物车

EasySep™ PE正选试剂盒 II

PE 偶联抗体标记细胞的免疫磁珠正选
率先评论此产品
添加并比较

产品号 #（选择产品）

产品号 #17684_C

PE 偶联抗体标记细胞的免疫磁珠正选

产品优势

  • 快捷、操作简单          
  • 无需分离柱

产品组分包括

  • EasySep™ PE 正选试剂盒 II（产品号 #17684）
    • EasySep™ PE分选抗体混合物，1 mL
    • EasySep™ Dextran RapidSpheres™磁珠，1 mL
    • RoboSep™ 偶联一抗专用管（手动操作无需使用），1支
  • RoboSep™ PE正选 试剂盒 II (产品号 #17684RF)
    • EasySep™ PE分选抗体混合物，1 mL
    • EasySep™ Dextran RapidSpheres™磁珠，1 mL
    • RoboSep™ 偶联一抗专用管（手动操作无需使用），1支
    • RoboSep™ 缓冲液（产品号 #20104）
    • RoboSep™ 过滤吸头（产品号 #20125）x 2
main product photo
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
总览
产品说明书及文档
相关材料与文献
相关产品

总览

使用EasySep™ PE正选 试剂盒 II，通过免疫磁珠正选，可从任何单细胞悬液样本中分离高纯度的藻红蛋白(PE)偶联抗体标记的细胞。EasySep™结合了单克隆抗体的特异性和无柱磁性系统的简便性，迄今已广泛应用于发表的研究中超过20年。    

在此EasySep™正选过程中，目的细胞被识别PE的抗体复合物和磁珠结合标记，使用EasySep™进行无柱分选，只需倾倒或吸弃非目的 细胞，目标细胞则保留在管中。磁珠分选获得的PE阳性细胞即可用于下游应用。

该产品可替代EasySep™PE 正选试剂盒 (产品号 #18557) 以进行更快的细胞分选。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
 
亚型
细胞分选试剂盒
 
细胞类型
B 细胞，树突状细胞（DCs），粒细胞及其亚群，造血干/祖细胞，巨噬细胞，骨髓基质细胞，间充质干/祖细胞，单核细胞，单个核细胞，髓系细胞，NK 细胞，其它细胞系，血浆，T 细胞
 
种属
非人灵长类，其它细胞系，大鼠
 
样本来源
Bone Marrow，Buffy Coat，Cord Blood，Leukapheresis，其它细胞系，PBMC，外周血，Spleen
 
筛选方法
Positive
 
应用
细胞分选
 
品牌
EasySep，RoboSep
 
研究领域
免疫
 

查看更多 显示更少

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
EasySep™ PE Positive Selection Kit II
Catalog #
17684
Lot #
All
Language
English
Document Type
Product Information Sheet
Product Name
RoboSep™ PE Positive Selection Kit II
Catalog #
17684RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
EasySep™ PE Positive Selection Kit II
Catalog #
17684
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
EasySep™ PE Positive Selection Kit II
Catalog #
17684
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
RoboSep™ PE Positive Selection Kit II
Catalog #
17684RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
RoboSep™ PE Positive Selection Kit II
Catalog #
17684RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Product Name
RoboSep™ PE Positive Selection Kit II
Catalog #
17684RF
Lot #
All
Language
English

Resources and Publications

Educational Materials (6)

EasySep™ Cell Separation Technology
Brochure
EasySep™ Cell Separation Technology
Tools for Your Immunology Research
Brochure
Tools for Your Immunology Research
Human Immune Cytokines
Wallchart
Human Immune Cytokines
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
1:13
Video
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
1:57
Video
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
How to Isolate PBMCs from Whole Blood Using Density Gradient Centrifugation (Ficoll™ or Lymphoprep™)
1:37
Video
How to Isolate PBMCs from Whole Blood Using Density Gradient Centrifugation (Ficoll™ or Lymphoprep...

Publications (5)

FACS and immunomagnetic isolation of early erythroid progenitor cells from mouse fetal liver. T. W. Braun et al. STAR protocols 2022 mar

Abstract

Early erythroid progenitors are transit-amplifying cells with high proliferative capacity committed to undergoing red cell differentiation. CD71/CD24low progenitors are less mature and have greater proliferative capacity than CD71/CD24high. We present protocols for isolation of CD71/CD24low progenitors from mouse fetal liver using both fluorescence-activated cell sorting (FACS) and immunomagnetic enrichment. CD71/CD24low progenitors isolated with both approaches show similar transcriptomes at single-cell resolution and exhibit characteristic proliferative responses to glucocorticoids. For complete details on the use and execution of this protocol, please refer to Li et al. (2019).
View publication
Androgen receptor activity in T cells limits checkpoint blockade efficacy. X. Guan et al. Nature 2022 jun

Abstract

Immune checkpoint blockade has revolutionized the field of oncology, inducing durable anti-tumour immunity in solid tumours. In patients with advanced prostate cancer, immunotherapy treatments have largely failed1-5. Androgen deprivation therapy is classically administered in these patients to inhibit tumour cell growth, and we postulated that this therapy also affects tumour-associated T cells. Here we demonstrate that androgen receptor (AR) blockade sensitizes tumour-bearing hosts to effective checkpoint blockade by directly enhancing CD8 T cell function. Inhibition of AR activity in CD8 T cells prevented T cell exhaustion and improved responsiveness to PD-1 targeted therapy via increased IFN$\gamma$ expression. AR bound directly to Ifng and eviction of AR with a small molecule significantly increased cytokine production in CD8 T cells. Together, our findings establish that T cell intrinsic AR activity represses IFN$\gamma$ expression and represents a novel mechanism of immunotherapy resistance.
View publication
Myeloid cell-targeted miR-146a mimic inhibits NF-$\kappa$B-driven inflammation and leukemia progression in vivo. Y.-L. Su et al. Blood 2020 jan

Abstract

NF-$\kappa$B is a key regulator of inflammation and cancer progression, with an important role in leukemogenesis. Despite its therapeutic potential, targeting NF-$\kappa$B using pharmacologic inhibitors has proven challenging. Here, we describe a myeloid cell-selective NF-$\kappa$B inhibitor using an miR-146a mimic oligonucleotide conjugated to a scavenger receptor/Toll-like receptor 9 agonist (C-miR146a). Unlike an unconjugated miR146a, C-miR146a was rapidly internalized and delivered to the cytoplasm of target myeloid cells and leukemic cells. C-miR146a reduced expression of classic miR-146a targets (IRAK1 and TRAF6), thereby blocking activation of NF-$\kappa$B in target cells. IV injections of C-miR146a mimic to miR-146a-deficient mice prevented excessive NF-$\kappa$B activation in myeloid cells, and thus alleviated myeloproliferation and mice hypersensitivity to bacterial challenge. Importantly, C-miR146a showed efficacy in dampening severe inflammation in clinically relevant models of chimeric antigen receptor (CAR) T-cell-induced cytokine release syndrome. Systemic administration of C-miR146a oligonucleotide alleviated human monocyte-dependent release of IL-1 and IL-6 in a xenotransplanted B-cell lymphoma model without affecting CD19-specific CAR T-cell antitumor activity. Beyond anti-inflammatory functions, miR-146a is a known tumor suppressor commonly deleted or expressed at reduced levels in human myeloid leukemia. Using The Cancer Genome Atlas acute myeloid leukemia data set, we found an inverse correlation of miR-146a levels with NF-$\kappa$B-related genes and with patient survival. Correspondingly, C-miR146a induced cytotoxic effects in human MDSL, HL-60, and MV4-11 leukemia cells in vitro. The repeated IV administration of C-miR146a inhibited expression of NF-$\kappa$B target genes and thereby thwarted progression of disseminated HL-60 leukemia. Our results show the potential of using myeloid cell-targeted miR-146a mimics for the treatment of inflammatory and myeloproliferative disorders.
View publication
View All Publications

更多信息

更多信息
Species Non-Human Primate, Other, Rat
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
Sample Source Bone Marrow, Buffy Coat, Cord Blood, Leukapheresis, Other, PBMC, Peripheral Blood, Spleen
Selection Method Positive
Legal Statement: Users of this kit should ensure that they are entitled to use the antibody of interest. STEMCELL Technologies Inc. is not responsible for patent infringements or violations that may occur when using this product. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
  • Scientists Helping Scientists™
  • ISO 13485 和 ISO 9001 质量管理体系认证
    ISO 14001 环境管理体系认证

Scientists Helping Scientists™

ISO 13485 和 ISO 9001 质量管理体系认证

ISO 14001 环境管理体系认证

版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。